Related references
Note: Only part of the references are listed.Why have ovarian cancer mortality rates declined? Part II. Case-fatality
Victoria Sopik et al.
GYNECOLOGIC ONCOLOGY (2015)
Why have ovarian cancer mortality rates declined? Part I. Incidence
Victoria Sopik et al.
GYNECOLOGIC ONCOLOGY (2015)
Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions
Johnathan M. Lancaster et al.
GYNECOLOGIC ONCOLOGY (2015)
Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer: An Analysis of GOG 182
Neil S. Horowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
Devansu Tewari et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
David D. Bowtell et al.
NATURE REVIEWS CANCER (2015)
Better Therapeutic Trials in Ovarian Cancer
Michael A. Bookman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata et al.
LANCET ONCOLOGY (2014)
The Role of Intraoperative Radiation Therapy in the Management of Recurrent and Locally Advanced Gynecologic Cancers
Olivia W. Foley et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
Noriyuki Katsumata et al.
LANCET ONCOLOGY (2013)
A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study
Robert S. Mannel et al.
GYNECOLOGIC ONCOLOGY (2011)
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study
John K. Chan et al.
GYNECOLOGIC ONCOLOGY (2010)
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:: A Gynecologic Oncology Group study
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2006)
Share Paper
